Assessment of low-dose ASA discontinuation risk associated with concomitant PPI use during the first year of ASA therapy
Study identifier:D5040N00008
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Assessment of low-dose ASA discontinuation risk associated with concomitant PPI use during the first year of ASA therapy for secondary prevention
Medical condition
Cardiovascular prevention
Phase
-
Healthy volunteers
No
Study drug
Risk of low dose aspirin discontinuation
Sex
All
Actual Enrollment
35604
Study type
Observational
Age
50 Years - 84 Years
Date
Study Start Date: 01 Sept 2012
Primary Completion Date: 01 Jun 2013
Study Completion Date: 01 Jun 2013
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Dec 2014 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Aspirin discontinuers; Aspirin non-discontinuers Patients on low dose ASA for secondary prevention that discontinue aspirin and those not discontinuing aspirin | Drug: Risk of low dose aspirin discontinuation PPI continuous use; No PPI usePPI |
| Drug PPI continuous use; No PPI use | - |
Contacts
Investigators
Principal Investigator
Luis A Garcia Rodriguez
CEIFE (Centro Espanol de Investigacion Farmacoepidemiologica - Spanish Centre for Pharmacoepidemiologic Research )
